Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of Candidemia in Swiss Tertiary Care hospitals: secular trends, 1991–2000. Clin Infect Dis. 2004;38:311–20.

Article  PubMed  Google Scholar 

Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20:5–10.

Article  PubMed  Google Scholar 

Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med. 2014;40:1303–12.

Article  PubMed  PubMed Central  Google Scholar 

Magill SS, O’Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, et al. Changes in prevalence of Health Care–Associated infections in U.S. hospitals. N Engl J Med. 2018;379:1732–44.

Article  PubMed  PubMed Central  Google Scholar 

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice Guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis off Publ Infect Dis Soc Am. 2016;62:e1–50.

Article  Google Scholar 

Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18:19–37.

Article  CAS  PubMed  Google Scholar 

Liu J, Balasubramanian MK. 1,3-beta-glucan synthase: a useful target for antifungal drugs. Curr Drug Targets - Infect Disord. 2001;1:159–69.

Article  CAS  PubMed  Google Scholar 

Denning DW. Echinocandin antifungal drugs. LANCET. 2003;362.

Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population Pharmacokinetic Analysis of Anidulafungin, an Echinocandin Antifungal. J Clin Pharmacol. 2004;44:590–8.

Article  CAS  PubMed  Google Scholar 

Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. Vivo comparison of the pharmacodynamic targets for Echinocandin drugs against Candida Species. Antimicrob Agents Chemother. 2010;54:2497–506.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, et al. In vivo pharmacodynamic characterization of Anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52:539–50.

Article  CAS  PubMed  Google Scholar 

Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB. In Vitro and in vivo studies to characterize the Clearance mechanism and potential cytochrome P450 interactions of Anidulafungin. Antimicrob Agents Chemother. 2009;53:1149–56.

Article  CAS  PubMed  Google Scholar 

Abdul-Aziz MH, Alffenaar J-WC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position Paper#. Intensive Care Med. 2020;46:1127–53.

Article  PubMed  PubMed Central  Google Scholar 

Liu X, Liu D, Pan Y, Li Y. Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: a systematic review and meta-analysis. J Clin Pharm Ther. 2020;45:1207–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alsowaida YS, Alamer A, Thabit AK, Almulhim AS, Aleissa MM, Kalbasi A, et al. Echinocandin exposures in obese patients: a scoping review and clinical perspectives. Am J Health Syst Pharm. 2023;80:503–17.

Article  PubMed  Google Scholar 

Levey AS, Stevens LA, Schmid CH, Zhang Y (Lucy), Castro AF, Feldman HI A New Equation to Estimate Glomerular Filtration Rate, et al. editors. Ann Intern Med. 2009;150:604–12.

Anidulafungin. EUCAST rationale document.

Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. [cited 2023 Jul 21]; https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-pharmacokinetics-pharmacodynamics-development-antimicrobial-medicinal-products_en.pdf

Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol. 2022;75:25–36.

Article  PubMed  PubMed Central  Google Scholar 

Wickham H. The tidyverse [Internet]. Presentation. 2016. Available from: http://tidyverse.org

Grolemund HW. and G. Welcome| R for Data Science [Internet]. [cited 2023 Jan 11]. https://r4ds.had.co.nz/

Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.

Article  PubMed  PubMed Central  Google Scholar 

Keizer RJ, Karlsson MO, Hooker A. Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacomet Syst Pharmacol. 2013;2:50.

Article  Google Scholar 

Baron KT. mrgsolve: Simulate from ODE-Based Models.

Dupont H, Massias L, Jung B, Ammenouche N, Montravers P. Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis. J Antimicrob Chemother. 2017;72:1429–32.

CAS  PubMed  Google Scholar 

Xie R, McFadyen L, Raber S, Swanson R, Tawadrous M, Leister-Tebbe H, et al. Population Analysis of Anidulafungin in infants to older adults with confirmed or suspected invasive candidiasis. Clin Pharmacol Ther. 2020;108:316–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hall RG, Liu S, Putnam WC, Kallem R, Gumbo T, Pai MP. Optimizing anidulafungin exposure across a wide adult body size range. Antimicrob Agents Chemother. 2023;67:e00820–23.

Kapralos I, Mainas E, Apostolopoulou O, Siopi M, Neroutsos E, Apostolidi S, et al. Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability. Br J Clin Pharmacol. 2021;87:1024–32.

Article  CAS  PubMed  Google Scholar 

Liu P, Mould DR. Population Pharmacokinetic-Pharmacodynamic analysis of Voriconazole and Anidulafungin in Adult patients with invasive aspergillosis. Antimicrob Agents Chemother. 2014;58:4727–36.

Article  PubMed  PubMed Central  Google Scholar 

Wasmann RE, ter Heine R, van Dongen EP, Burger DM, Lempers VJ, Knibbe CA, et al. Pharmacokinetics of Anidulafungin in obese and normal-weight adults. Antimicrob Agents Chemother. 2018;62:e00063–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brüggemann RJM, Van Der Velden WJFM, Knibbe CAJ, Colbers A, Hol S, Burger DM, et al. A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. J Antimicrob Chemother. 2015;70:1166–74.

Article  PubMed  Google Scholar 

Liu P, Ruhnke M, Meersseman W, Paiva JA, Kantecki M, Damle B. Pharmacokinetics of Anidulafungin in critically ill patients with Candidemia/Invasive candidiasis. Antimicrob Agents Chemother. 2013;57:1672–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malbrain MLNG, Marik PE, Witters I, Cordemans C, Kirkpatrick AW, Roberts DJ, et al. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. Anestezjol Intensywna Ter. 2014;46:361–80.

Google Scholar 

National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in Acute Lung Injury. N Engl J Med. 2006;354(24):2564–75.

Ruhnke M, Paiva JA, Meersseman W, Pachl J, Grigoras I, Sganga G, et al. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect. 2012;18:680–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kullberg BJ, Vasquez J, Mootsikapun P, Nucci M, Paiva J-A, Garbino J, et al. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. J Antimicrob Chemother. 2017;72:2368–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dimopoulos G, Paiva J-A, Meersseman W, Pachl J, Grigoras I, Sganga G, et al. Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis. Int J Antimicrob Agents. 2012;40:521–6.

Article  CAS  PubMed  Google Scholar 

Kim HY, Baldelli S, Märtson A-G, Stocker S, Alffenaar J-W, Cattaneo D, et al. Therapeutic drug monitoring of the Echinocandin Antifungal agents: is there a role in clinical practice? A position Statement of the Anti-infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2022;44:198–214.

Article  CAS  PubMed